Anne E Nigra1, Barbara V Howard2, Jason G Umans2, Lyle Best3, Kevin A Francesconi4, Walter Goessler4, Richard Devereux5, Ana Navas-Acien6. 1. Columbia University Mailman School of Public Health, Department of Environmental Health Sciences, New York, NY, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: aen2136@cumc.columbia.edu. 2. MedStar Health Research Institute, Washington, DC, USA; Georgetown/Howard Universities Center for Clinical and Translational Sciences, USA. 3. Epidemiology Department, Missouri Breaks Industries Research Inc., Timber Lake, SD, USA. 4. Institute of Chemistry, University of Graz, Graz, Austria. 5. Weill Cornell Medical College, New York, NY, USA. 6. Columbia University Mailman School of Public Health, Department of Environmental Health Sciences, New York, NY, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Abstract
BACKGROUND: Tungsten (W) interferes with molybdenum (Mo) binding sites and has been associated with prevalent cardiovascular disease (CVD). We evaluated if (1) W exposure is prospectively associated with incident CVD and (2) the association between urinary W levels and incident CVD is modified by urinary Mo levels. METHODS: We estimated multi-adjusted hazard ratios (HRs) for incident CVD outcomes by increasing W levels for 2726 American Indian participants in the Strong Heart Study with urinary metal levels measured at baseline (1989-1991) and CVD events ascertained through 2008. RESULTS: Increasing levels of baseline urinary W were not associated with incident CVD. Fully-adjusted HRs (95% CIs) of incident CVD comparing a change in the IQR of W levels for those in the lowest and highest tertile of urinary Mo were 1.05 (0.90, 1.22) and 0.80 (0.70, 0.92), respectively (p-interaction = 0.02); for CVD mortality, the corresponding HRs were 1.05 (0.82, 1.33) and 0.73 (0.58, 0.93), respectively (p-interaction = 0.03). CONCLUSIONS: The association between W and CVD incidence and mortality was positive although non-significant at lower urinary Mo levels and significant and inverse at higher urinary Mo levels. Although prior cross-sectional epidemiologic studies in the general US population found positive associations between urinary tungsten and prevalent cardiovascular disease, our prospective analysis in the Strong Heart Study indicates this association may be modified by molybdenum exposure.
BACKGROUND:Tungsten (W) interferes with molybdenum (Mo) binding sites and has been associated with prevalent cardiovascular disease (CVD). We evaluated if (1) W exposure is prospectively associated with incident CVD and (2) the association between urinary W levels and incident CVD is modified by urinary Mo levels. METHODS: We estimated multi-adjusted hazard ratios (HRs) for incident CVD outcomes by increasing W levels for 2726 American Indian participants in the Strong Heart Study with urinary metal levels measured at baseline (1989-1991) and CVD events ascertained through 2008. RESULTS: Increasing levels of baseline urinary W were not associated with incident CVD. Fully-adjusted HRs (95% CIs) of incident CVD comparing a change in the IQR of W levels for those in the lowest and highest tertile of urinary Mo were 1.05 (0.90, 1.22) and 0.80 (0.70, 0.92), respectively (p-interaction = 0.02); for CVD mortality, the corresponding HRs were 1.05 (0.82, 1.33) and 0.73 (0.58, 0.93), respectively (p-interaction = 0.03). CONCLUSIONS: The association between W and CVD incidence and mortality was positive although non-significant at lower urinary Mo levels and significant and inverse at higher urinary Mo levels. Although prior cross-sectional epidemiologic studies in the general US population found positive associations between urinary tungsten and prevalent cardiovascular disease, our prospective analysis in the Strong Heart Study indicates this association may be modified by molybdenum exposure.
Authors: E T Lee; T K Welty; R Fabsitz; L D Cowan; N A Le; A J Oopik; A J Cucchiara; P J Savage; B V Howard Journal: Am J Epidemiol Date: 1990-12 Impact factor: 4.897
Authors: Jürgen Scheer; Silvia Findenig; Walter Goessler; Kevin A Francesconi; Barbara Howard; Jason G Umans; Jonathan Pollak; Maria Tellez-Plaza; Ellen K Silbergeld; Eliseo Guallar; Ana Navas-Acien Journal: Anal Methods Date: 2012-01-20 Impact factor: 2.896
Authors: Maria Tellez-Plaza; Eliseo Guallar; Barbara V Howard; Jason G Umans; Kevin A Francesconi; Walter Goessler; Ellen K Silbergeld; Richard B Devereux; Ana Navas-Acien Journal: Epidemiology Date: 2013-05 Impact factor: 4.822
Authors: Jessica Tyrrell; Tamara S Galloway; Ghada Abo-Zaid; David Melzer; Michael H Depledge; Nicholas J Osborne Journal: PLoS One Date: 2013-11-11 Impact factor: 3.240
Authors: Gernot Pichler; Maria Grau-Perez; Maria Tellez-Plaza; Jason Umans; Lyle Best; Shelley Cole; Walter Goessler; Kevin Francesconi; Jonathan Newman; Josep Redon; Richard Devereux; Ana Navas-Acien Journal: Circ Cardiovasc Imaging Date: 2019-05 Impact factor: 7.792
Authors: Carlos Jiménez-Cortegana; Pedro Iglesias; Josep Ribalta; Teresa Vilariño-García; Laura Montañez; Francisco Arrieta; Manuel Aguilar; Santiago Durán; Juan C Obaya; Antonio Becerra; Juan Pedro-Botet; Víctor Sánchez-Margalet Journal: Nutrients Date: 2021-11-19 Impact factor: 5.717